Current Hepatology Reports

, Volume 17, Issue 2, pp 83–87 | Cite as

Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations

  • Joseph K. Lim
Invited Commentary


Chronic hepatitis C virus (HCV) infection remains a global public health burden and is associated with significant morbidity and mortality. Despite significant advances in the safety and efficacy of antiviral therapy since 2014 due to the rise of oral direct acting antiviral (DAA) regimens, ongoing deficits persist across the care cascade in the USA which will limit success in achieving the objectives of the US National Academies of Sciences, Engineering, and Medicine and the World Health Organization to eliminate chronic HCV in the USA and worldwide. In this review, we discuss the critical role of expanding treatment capacity to enhance these efforts through a multifaceted strategy which incorporates education, training, and multidisciplinary support across clinical settings such as specialty centers, primary care, community health centers, methadone and substance use programs, prisons, and pharmacy-based clinics. Further investment by multiple stakeholders including governmental and non-governmental organizations, public health agencies, medical societies, and advocacy groups will be necessary to meaningfully effect change.


Hepatitis C Direct acting antivirals Care cascade Capacity Public health Elimination Access 


Compliance with Ethical Standards

Conflict of Interest

Joseph K. Lim reports grants from AbbVie, grants from Allergan, grants from Bristol-Myers Squibb, grants from Genfit, grants from Gilead, grants from Intercept, grants from Conatus, personal fees from Bristol-Myers Squibb, and personal fees from Gilead, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–35.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sarkar S, Lim JK. Advances in interferon-free hepatitis C therapy: 2014 and beyond. Hepatology. 2014;59:1641–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, et al. Safety and effectiveness of ledipasvir and sofosbuvir with or without ribavirin in treatment-experienced patients with genotype 1 hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol. 2018; 3.Google Scholar
  4. 4.
    Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 2017;66:1844–52.CrossRefPubMedGoogle Scholar
  5. 5.
    Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response (SVR). Gastroenterology. 2016;151:1131–40.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–16.CrossRefPubMedGoogle Scholar
  7. 7.
    Reddy KR, Lim JK, Kuo A, Di Biscelgie AM, Galati JS, Morelli G, et al. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther. 2017;45:115–26.CrossRefPubMedGoogle Scholar
  8. 8.
    Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150:419–29.CrossRefPubMedGoogle Scholar
  9. 9.
    Backus LI, Belperio PS, Shahoumian TA, Mole LA Impact of sustained virologic response with direct-acting antiviral treatment in patients with advanced liver disease. Hepatology 2017.Google Scholar
  10. 10.
    Backus LI, Belperio PS, Shahoumain TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology 2018; 29Google Scholar
  11. 11.
    Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2017; 5.Google Scholar
  12. 12.
    Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination—a path to global elimination of hepatitis C. J Hepatol. 2017;67:665–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Calvaruso V, Petta S, Craxi A. Is global elimination of HCV realistic? Liver Int. 2018;38(Suppl 1):40–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Yehia BR, Schranz AJ, Umscheld CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9:e101554.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sarkar S, Esserman DA, Skanderson M, et al. Disparities in hepatitis C testing in U.S. veterans born 1945-1965. J Hepatol. 2016;65:259–65.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    •• Belperio PS, Chartier M, Ross DB. Curing hepatitis C virus infection: best practices from the U.S. Department of Veterans Affairs. Ann Intern Med. 2017;167:499–504. Landmark paper which outlines the unique model of success of the national V.A. system to treat more than 92,000 HCV-infected veterans since 2014 through a combination of infrastructure development,electronic data tools, integrated care, and expansion of treatment capacity through use of nonphysicianproviders.CrossRefPubMedGoogle Scholar
  17. 17.
    LaMattina J. The VA will eliminate hepatitis C in veterans by year-end. Forbes 2018; 1.Google Scholar
  18. 18.
    Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64:1442–50.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Meyer JP, Moghimi Y, Marcus R, et al. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. Int J Drug Policy. 2015;26:922–35.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zhou FT, Walsh N, et al. Interventions to optimize the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. Lancet Infect Dis. 2016;16:1409–22.CrossRefPubMedGoogle Scholar
  21. 21.
    Scott N, Doyle JS, Wilson DP, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015; a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–76.CrossRefGoogle Scholar
  23. 23.
    • Jemal A, Fedewa SA. Recent hepatitis C virus testing patterns among baby boomers. Am J Prev Med. 2017;53:e31–3. Analysis of 2013 and 2015 National Health Interview Survey data which reveals ongoing deficits in HCV screening among baby boomer Americans.CrossRefPubMedGoogle Scholar
  24. 24.
    Konerman MA, Thomson M, Gray K, et al.. Impact of an electronic health record alert in primary care on increasing hepatitis C screening and curative treatment for baby boomers. Hepatology 2017.Google Scholar
  25. 25.
    Noska AJ, Belperiod PS, Loomis TP, et al. Engagement in the hepatitis C care cascade among homeless veterans, 2015. Public Health Rep. 2017;132:136–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Franco RA, Overton ET, Tamhane AR, et al. Characterizing failure to establish hepatitis C care of baby boomers diagnosed in the emergency department. Open Forum Infect Dis. 2016;3:ofw211.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hochstatter KR, Stockman LJ, Holzmacher R, et al. The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care. Health Justice. 2017;5:10.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Do A, Mittal Y, Liapakis A, et al. Drug authorization for sofosbuvir/ledipasvir (Harvoni) for chronic HCV infection in a real-world cohort: a new barrier in the HCV care cascade. PLoS One. 2015;10:e0135645.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lo Re V 3rd, Gowda C, Urick PN, et al. Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol. 2016;14:1035–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Barua S, Greenwald R, Grebely J, et al. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015;163:215–23.CrossRefPubMedGoogle Scholar
  31. 31.
    Ooka CJJ, Lim JK. Medicaid reimbursement for oral direct antiviral agents for the treatment of chronic hepatitis C. Am J Gastroenterol. 2017;112:828–32.CrossRefPubMedGoogle Scholar
  32. 32.
    Reau N, Fried MW, Nelson DR, Brown RS Jr, Everson GT, Gordon SC, et al. HCV Council—critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016;36:488–502.CrossRefPubMedGoogle Scholar
  33. 33.
    Arora S, Thornton K, Murata G, et al. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;365:2199–207.CrossRefGoogle Scholar
  34. 34.
    Mitruka K, Thornton K, Cusick S, et al. Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model—Arizona and Utah, 2012-2014. MMWR Morb Mortal Wkly Rep. 2014;63:393–8.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Ni Cheallaigh C, O’Leary A, Keating S, et al. Telementoring with project ECHO: a pilot study in Europe. BMJ Innov. 2017;3:144–51.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Marciano S, Haddad L, Piazzotta F, et al. Implementation of the ECHO telementoring model for the treatment of patients with hepatitis C. J Med Virol. 2017;89:660–4.CrossRefPubMedGoogle Scholar
  37. 37.
    Tahan V, Almashhrawi A, Mutrux R, Ibdah JA. Show Me ECHO-hepatitis C: a telemedicine mentoring program for patients with hepatitis C in underserved and rural areas in Missouri as a model in developing countries. Turk J Gastroenterol. 2015;26:447–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Rattay T, Dumont IP, Heinzow HS, Hutton DW. Cost-effectiveness of access expansion to treatment of hepatitis C virus infection through primary care providers. Gastroenterology. 2017;153:1531–1543.e2.CrossRefPubMedGoogle Scholar
  39. 39.
    Backus LI, Boothroyd DB, Phillips BR, et al. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology. 2007;46:37–47.CrossRefPubMedGoogle Scholar
  40. 40.
    Norton BL, Fleming J, Bachhuber MA, et al. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. Int J Drug Policy. 2017;47:196–201.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    •• Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017. Pivotal prospective clinical trial in 13 urban, federally qualified health centers (FQHCs) demonstrating feasibility of HCV treatment by community-based non-specialist providers.Google Scholar
  42. 42.
    Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat. 2001;8:377–83.CrossRefPubMedGoogle Scholar
  43. 43.
    Falade-Nwulia O, McAdams-Mahmoud A, Irvin R, et al. Primary care providers knowledge, attitude, and practices related to hepatitis C screening and treatment in the oral direct acting antiviral agents era. J Community Med Health Educ. 2016.Google Scholar
  44. 44.
    Camminati CW, Simha A, Kolb NR, Prasad R. Intent to build hepatitis C treatment capacity within family medicine residencies: a nationwide survey of program directors: a CERA study. Fam Med. 2016;48:631–4.Google Scholar
  45. 45.
    Haynes R, Jones C, Seigle A, et al. Outcomes of patients treated with direct acting antiviral agents for hepatitis C: the Bridgeport Hospital Experience. Conn Med. 2017;81:517–23.Google Scholar
  46. 46.
    Kwong J, Epstein R. Expanding capacity for hepatitis C treatment in the United States: teambased care and use of nonphysician providers. J Int Assoc Provid AIDS Care. 2015;14:112–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Jayasekera CR, Beckerman R, Smith N, et al. Sofosbuvir-based regimens with task shifting is cost-effective in expanding hepatitis C treatment access in the United States. J Clin Transl Hepatol. 2017;5:16–22.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Yoo ER, Perumpail RB, Cholankeril G, et al. The role of e-health in optimizing task-shifting in the delivery of antiviral therapy for chronic hepatitis C. Telemed J E Health. 2017;23:870–3.CrossRefPubMedGoogle Scholar
  49. 49.
    Gauthier TP, Moreira E, Chan C, et al. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution. J Am Pharm Assoc. 2016;56:670–6.CrossRefGoogle Scholar
  50. 50.
    Lasser KE, Heinz A, Battisti L, et al. A hepatitis C treatment program based in a safety-net hospital patient-centered medical home. Ann Fam Med. 2017;15:258–61.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Sokol R, Early J, Barner A, et al. Implementation of a multidisciplinary, team-based model to treat chronic hepatitis C in the primary care setting: lessons learned. HealthC. 2017.Google Scholar
  52. 52.
    Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med. 2017.Google Scholar
  53. 53.
    Groessl EJ, Liu L, Sklar M, Ho SB. HCV integrated care: a randomized trial to increase treatment initiation and SVR with direct acting antivirals. Int J Hepatol. 2017.Google Scholar
  54. 54.
    Ranieri R, Starnini G, Carbonara S, et al. Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel. Infection. 2017;45:131–8.CrossRefPubMedGoogle Scholar
  55. 55.
    • He T, Li K, Roberts MS, et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. 2016;164:84–92. NIH-funded agent-based microsimulation model analysis which reveals the clinical and economic impact of opt-out screening and treatment of HCV in the U.S. prison system.CrossRefPubMedGoogle Scholar
  56. 56.
    Beckman AL, Bilinski A, Boyko R, et al. New hepatitis C drugs are very costly and unavailable to many state prisoners. Health Aff. 2016;35:1893–901.CrossRefGoogle Scholar
  57. 57.
    Shiffman ML. The next wave of hepatitis C virus: the epidemic of intravenous drug use. Liver Int. 2018;38(Suppl 1):34–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Bruce RD, Eiserman J, Acosta, et al. Developing a modified direct observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse. 2012;38:206–12.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicenter trial. Lancet Gastroenterol Hepatol. 2018; 5.Google Scholar

Copyright information

© This is a U.S. government work and its text is not subject to copyright protection in the United States; however, its text may be subject to foreign copyright protection 2018

Authors and Affiliations

  1. 1.Section of Digestive Diseases, Yale Liver CenterYale University School of MedicineNew HavenUSA

Personalised recommendations